SC
HALO icon

Stephens Consulting’s Halozyme HALO Stock Holding History

Stephens Consulting’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-35
Closed -$2.23K – 1525
2025
Q1 		$2.23K Buy
+35
New +$2.03K ﹤0.01% 434
2024
Q3 		– Sell
-68
Closed -$3.56K – 573
2024
Q2 		$3.56K Buy
+68
New +$2.98K ﹤0.01% 444

Other funds holding HALO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Stephens Consulting's HALO Position: Q2 2025 in Review

Stephens Consulting sold out of Halozyme (HALO) in Q2 2025, closing a stake of 35 shares — an estimated $2.23K sold.

Stephens Consulting first reported a position in HALO in Q2 2024 and held it in 2 quarters. The position peaked at $3.56K in Q2 2024. 551 funds tracked by Wall St. Rank hold HALO as of Q2 2025.

  • Stephens Consulting reported no remaining Halozyme position as of Q2 2025 after selling out during the quarter.
  • Stephens Consulting sold 35 Halozyme shares in Q2 2025, an estimated $2.23K.
  • Stephens Consulting first reported a position in Halozyme in Q2 2024 and held it in 2 quarters.
  • Stephens Consulting's Halozyme position peaked at $3.56K in Q2 2024.
  • 551 funds tracked by Wall St. Rank held Halozyme as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.